Related Experiment Video

Updated: Aug 9, 2026

Ovariectomy and 17β-estradiol Replacement in Rats and Mice: A Visual Demonstration
06:51

Ovariectomy and 17β-estradiol Replacement in Rats and Mice: A Visual Demonstration

Published on: June 7, 2012

Effect of treatment with different doses of 17-beta-estradiol on insulin receptor substrate-1

C González1, A Alonso, N A Grueso

  • 1Department of Functional Biology, Physiology Area, University of Oviedo. Oviedo, Spain. tinog@correo.uniovi.es

JOP : Journal of the Pancreas
|March 5, 2002
PubMed
Abstract

Insights

Estradiol dose impacts insulin sensitivity by altering insulin receptor substrate 1 (IRS-1) levels. Low doses may improve sensitivity, while high doses can cause resistance, particularly in muscle and fat tissue.

Area of Science:

  • Endocrinology
  • Metabolic Research
  • Hormone Therapy

Background:

  • Ovarian hormones significantly influence insulin sensitivity, yet their precise mechanisms require further elucidation.
  • Understanding the role of hormones like 17-beta-estradiol is crucial for metabolic health.

Purpose of the Study:

  • To investigate how varying doses of 17-beta-estradiol affect insulin receptor substrate 1 (IRS-1) regulation.
  • To determine the implications of these changes on overall insulin sensitivity.

Main Methods:

  • Ovariectomized rats were administered different doses of 17-beta-estradiol over 6, 11, and 16 days.
  • Insulin receptor substrate 1 (IRS-1) levels were analyzed in various tissues using immunoprecipitation and Western blotting techniques.

Main Results:

  • 17-beta-estradiol treatment modulated IRS-1 levels in a tissue-specific, dose-dependent, and time-dependent manner.
  • The study observed distinct effects of estradiol on IRS-1 regulation across different tissues and treatment durations.

Conclusions:

  • Low 17-beta-estradiol concentrations may upregulate IRS-1, enhancing insulin sensitivity in muscle and adipose tissue.
  • High concentrations of 17-beta-estradiol were found to downregulate IRS-1, potentially promoting insulin resistance in peripheral tissues.
  • These findings highlight the complex role of 17-beta-estradiol in modulating IRS-1 and insulin sensitivity, with implications for women using hormonal therapies.

More Related Videos

Homogeneous Time-resolved Förster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion07:30

Homogeneous Time-resolved Förster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion

Published on: May 10, 2018

An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause06:18

An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause

Published on: August 13, 2019

Related Concept Videos

Insulin: The Receptor and Signaling Pathways01:28

Insulin: The Receptor and Signaling Pathways

Insulin action is mediated through a receptor tyrosine kinase, akin to the IGF-1 receptor. The number of receptors per cell varies significantly, from 40 on erythrocytes to 300,000 on adipocytes and hepatocytes. The insulin receptor consists of linked α/β subunit dimers, forming a heterotetramer glycoprotein with two extracellular α subunits and two β subunits spanning the membrane. The α subunits inhibit the inherent tyrosine kinase activity of the β subunits, but this inhibition is released...
Insulin: Dosing Regimen and Adverse Effects01:16

Insulin: Dosing Regimen and Adverse Effects

Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...